

November 5, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on November 5, 2025

The Board of Directors of the Company at its meeting held today, November 5, 2025, has, inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors.

The Board meeting commenced at 4.30 p.m. and concluded at 6.06 p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivi har, Ameerpet, Hyderabad-500038, Telangana, India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com



AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: info@aurobindo.com

(All amounts are in ₹ million, unless otherwise stated)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025						
	Particulars	Quarter ended			Half year ended	
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations					
	(a) Net sales/ income from operations	27,598.9	28,221.4	27,578.8	55,820.3	51,831.0
	(b) Other operating income	298.3	260.3	667.1	558.6	1,015.8
	Total revenue from operations	27,897.2	28,481.7	28,245.9	56,378.9	52,846.8
2	Other income					
	(a) Foreign exchange gain (net)	591.5	406.0	714.0	997.5	960.7
	(b) Others	1,003.7	431.7	512.6	1,435.4	919.1
	Total other income	1,595.2	837.7	1,226.6	2,432.9	1,879.8
3	Total income (1+2)	29,492.4	29,319.4	29,472.5	58,811.8	54,726.6
4	Expenses					
	(a) Cost of materials consumed	12,441.6	13,400.1	14,247.4	25,841.7	27,429.2
	(b) Purchase of stock-in-trade	221.5	143.8	161.6	365.3	297.6
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,012.7	384.8	(312.5)	1,397.5	(668.1)
	(d) Employee benefits expense	2,943.7	2,829.7	2,654.8	5,773.4	5,248.1
	(e) Finance costs	574.5	600.0	516.3	1,174.5	1,027.6
	(f) Depreciation and amortisation expenses	714.9	700.2	681.6	1,415.1	1,350.4
	(g) Other expenses	4,030.7	3,759.9	4,285.8	7,790.6	8,341.9
	Total expenses	21,939.6	21,818.5	22,235.0	43,758.1	43,026.7
5	Profit before tax (3-4)	7,552.8	7,500.9	7,237.5	15,053.7	11,699.9
6	Tax expense					
	Current tax	1,742.2	1,876.8	1,884.3	3,619.0	3,080.9
	Deferred tax	(3.1)	32.8	(22.1)	29.7	(46.7)
	Total tax expense	1,739.1	1,909.6	1,862.2	3,648.7	3,034.2
7	Profit after tax (5-6)	5,813.7	5,591.3	5,375.3	11,405.0	8,665.7
8	Other comprehensive income					
	Items that will not be reclassified subsequently to profit or loss:					
	(a) Re-measurement of defined benefit liability	(0.4)	(17.6)	(33.2)	(18.0)	(38.8)
	(b) Income-tax relating to items that will not be reclassified to profit or loss	0.1	4.4	8.4	4.5	9.8
	Other comprehensive loss	(0.3)	(13.2)	(24.8)	(13.5)	(29.0)
9	Total comprehensive income (7+8)	5,813.4	5,578.1	5,350.5	11,391.5	8,636.7
10	Paid-up equity share capital (face value ₹ 1 per share)	580.8	580.8	580.8	580.8	580.8
11	Other equity					2,04,760.3
12	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	Not annualised	Not annualised	(Annualised)
	(a) Basic (in ₹)	10.01	9.63	9.21	19.64	14.81
	(b) Diluted (in ₹)	10.01	9.63	9.21	19.64	14.81



4



Sl. No.	Particulars	As at	As at
		30.09.2025	31.03.2025
		Unaudited	Audited
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	22,855.7	21,664.9
	Capital work-in-progress	2,088.9	875.3
	Right-of-use assets	97.4	188.0
	Goodwill	917.0	917.0
	Other intangible assets	459.1	598.1
	Financial assets		
	Investments	1,64,361.3	1,52,095.6
	Loans	9,046.7	16,543.2
	Trade receivables	-	-
	Other financial assets	437.7	431.6
	Income tax assets (net)	2,654.9	2,791.5
	Other non-current assets	1,234.7	2,131.4
	Total non-current assets	2,04,153.4	1,98,236.6
2	Current assets		
	Inventories	22,835.6	23,592.8
	Financial assets		
	Investments	10.2	0.1
	Trade receivables	44,157.2	41,950.5
	Cash and cash equivalents	2,353.1	2,952.6
	Bank balances other than cash and cash equivalents	22.8	31.0
	Loans	58.9	54.4
	Other financial assets	1,970.3	2,062.7
	Other current assets	4,908.4	6,249.9
	Total current assets	76,316.5	76,894.0
	TOTAL ASSETS (1+2)	2,80,469.9	2,75,130.6
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	580.8	580.8
	Other equity	2,13,828.6	2,04,760.3
	Total equity	2,14,409.4	2,05,341.1
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	1,800.0	4,000.0
	Lease liabilities	27.5	37.2
	Provisions	773.5	533.0
	Deferred tax liability (net)	1,039.5	1,014.3
	Total non-current liabilities	3,640.5	5,584.5
3	Current liabilities		
	Financial liabilities		
	Borrowings	42,383.9	42,250.9
	Lease liabilities	73.9	177.9
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	595.5	378.4
	total outstanding dues of creditors other than micro enterprises and small enterprises	15,658.8	17,495.8
	Other financial liabilities	2,268.1	2,761.5
	Other current liabilities	501.3	290.4
	Provisions	260.6	213.5
	Current tax liabilities (net)	677.9	636.6
	Total current liabilities	62,420.0	64,205.0
	TOTAL EQUITY AND LIABILITIES (1+2+3)	2,80,469.9	2,75,130.6



K. - 11



Standalone Statement of Cash Flows

(All amounts are in ₹ million, unless otherwise stated)

Sl. No.	Particulars	For the half year ended 30.09.2025	For the half year ended 30.09.2024
		Unaudited	Unaudited
1	CASH FLOW FROM OPERATING ACTIVITIES		
	Net profit before tax	15,053.7	11,699.9
	Adjustments for :		
	Depreciation and amortisation expenses	1,415.1	1,350.4
	Allowance for expected credit losses (net)	(45.8)	68.4
	Unrealised foreign exchange gain (net)	(1,350.6)	(886.5)
	Profit on sale of property, plant and equipment (net)	(7.3)	(9.2)
	Dividend income	(705.6)	-
	Profit on sale of investments	-	(53.8)
	Finance costs	1,167.1	1,019.7
	Interest income	(597.4)	(678.3)
	Operating profit before working capital changes	14,929.2	12,510.6
	Movements in working capital:		
	(Increase)/decrease in trade receivables	145.6	2,280.6
	(Increase)/decrease in inventories	757.3	(1,014.9)
	(Increase)/decrease in loans	(9.0)	(2.9)
	(Increase)/decrease in other financial assets	(134.0)	(2,037.0)
	(Increase)/decrease in other assets	2,350.0	(403.1)
	Increase/(decrease) in trade payables	(1,813.3)	1,548.5
	Increase/(decrease) in provision for employee benefits	269.5	19.0
	Increase/(decrease) in other financial liabilities	(749.6)	586.0
	Increase/(decrease) in other liabilities	211.0	(426.6)
	Cash generated from operating activities	15,956.7	13,060.2
	Income-tax paid (net)	(3,441.0)	(3,154.9)
	Net cash flow generated from operating activities (A)	12,515.7	9,905.3
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment including movement in capital work-in-progress, capital advances and capital creditors	(3,370.2)	(1,203.7)
	Proceeds from sale of property, plant and equipment	188.3	(32.2)
	Purchase of non-current investments	(10,280.0)	(14,261.0)
	Proceeds from redemption of debentures	5,500.0	-
	Proceeds from sale of non-current investments	-	6,100.0
	Purchase of current investments	(10.0)	-
	Profit from sale of current investments	-	53.8
	Dividend received from subsidiaries	705.6	-
	Loans given to subsidiaries	(8,440.0)	(5,480.0)
	Loans repaid by subsidiaries	7,301.0	1,972.8
	Interest received	1,798.1	221.0
	Movement in other bank balances (net)	8.2	43.7
	Net cash flow used in investing activities (B)	(6,599.0)	(12,585.6)
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Buy back of equity shares (including tax and transaction cost)	-	(9,302.4)
	Proceeds from non current borrowings	1,800.0	4,400.0
	Repayment of non current borrowings	(1,258.3)	-
	Proceeds/(repayment) of current borrowings (net)	(3,536.5)	9,505.5
	Repayment of lease liabilities	(120.1)	(119.5)
	Interest paid	(1,174.5)	(999.5)
	Dividend paid	(2,321.9)	(1.5)
	Net cash generated from/(used in) financing activities (C)	(6,611.3)	3,482.6
	Net Increase/(decrease) in cash and cash equivalents (A+B+C)	(694.6)	802.3
	Cash and cash equivalents at the beginning of the year	2,952.6	833.2
	Effect of exchange differences on cash and cash equivalents	95.1	148.5
	Cash and cash equivalents at the end of the period	2,353.1	1,784.0
	Cash and cash equivalents comprises of:		
	Cash on hand	0.1	0.2
	Balance with banks	2,353.0	1,783.8
	Cash and cash equivalents considered for cash flows	2,353.1	1,784.0



u - 4



NOTES:

- 1 The above unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 5, 2025. The results for the quarter and half year ended September 30, 2025 has been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2025.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".

By Order of the Board
For Aurobindo Pharma Limited



K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195



Place: Hyderabad
Date : November 5, 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **AUROBINDO PHARMA LIMITED** ("the Company"), for the quarter and half year ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



C Manish Muralidhar
(Partner)

(Membership No. 213649)
(UDIN: 25213649BMOEPW2924)

Place: Hyderabad
Date: November 05, 2025



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025							
	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations						
	(a) Net sales/ income from operations	82,369.6	77,917.7	76,462.1	1,60,287.3	1,51,038.6	3,13,781.3
	(b) Other operating income	487.4	763.7	1,498.6	1,251.1	2,592.3	3,456.0
	Total revenue from operations	82,857.0	78,681.4	77,960.7	1,61,538.4	1,53,630.9	3,17,237.3
2	Other income						
	(a) Foreign exchange gain (net)	49.8	-	145.8	45.9	155.8	-
	(b) Others	1,156.1	1,053.0	1,214.2	2,209.1	3,413.5	6,218.5
	Total other income	1,205.9	1,053.0	1,360.0	2,255.0	3,569.3	6,218.5
	Total income (1+2)	84,062.9	79,734.4	79,320.7	1,63,793.4	1,57,200.2	3,23,455.8
3	Expenses						
	(a) Cost of materials consumed	25,098.0	25,351.6	27,418.5	50,449.6	52,085.1	1,07,367.6
	(b) Purchase of stock-in-trade	8,460.5	8,078.0	7,470.3	16,538.5	14,270.4	28,871.1
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(169.9)	(1,037.4)	(2,786.1)	(1,207.3)	(3,526.0)	(5,976.3)
	(d) Employee benefits expense	12,773.3	12,288.0	11,094.8	25,061.3	21,814.3	44,756.2
	(e) Finance costs	952.4	977.5	1,127.0	1,929.9	2,237.4	4,572.4
	(f) Foreign exchange loss (net)	-	3.9	-	-	-	226.5
	(g) Depreciation, amortisation and impairment expense	4,291.9	4,057.0	3,822.8	8,348.9	7,864.6	16,494.2
	(h) Other expenses	19,914.1	17,967.0	19,101.8	37,881.1	37,130.0	76,164.3
	Total expenses	71,320.3	67,685.6	67,249.1	1,39,002.0	1,31,875.8	2,72,476.0
4	Profit before share of profit/(loss) of associates and joint ventures, exceptional items and tax (1+2-3)	12,742.6	12,048.8	12,071.6	24,791.4	25,324.4	50,979.8
5	Share of profit/(loss) of associates and joint ventures, net of tax	16.6	19.2	3.0	35.8	(10.9)	(316.9)
6	Profit before tax (4+5)	12,759.2	12,068.0	12,074.6	24,827.2	25,313.5	50,662.9
7	Tax expense						
	Current tax	4,630.3	4,907.2	3,221.3	9,537.5	7,714.0	16,999.8
	Deferred tax	(352.4)	(1,081.2)	683.8	(1,433.6)	247.8	(1,172.6)
	Total tax expense	4,277.9	3,826.0	3,905.1	8,103.9	7,961.8	15,827.2
8	Profit after tax (6-7)	8,481.3	8,242.0	8,169.5	16,723.3	17,351.7	34,835.7
9	Other comprehensive Income						
	A) Items that will not be reclassified subsequently to profit or loss:						
	i) Re-measurement of defined employee benefit liability	(6.1)	(21.9)	(71.4)	(28.0)	(77.0)	(190.2)
	ii) Equity investments through other comprehensive income – net change in fair value	8.8	12.3	46.2	21.1	47.9	105.9
	iii) Income-tax relating to items that will not be reclassified to profit or loss	(0.7)	2.8	8.1	2.1	9.5	21.1
	B) Items that will be reclassified subsequently to profit or loss:						
	i) Exchange differences on translating the financial statements of foreign operations	5,408.7	4,065.2	2,719.9	9,473.9	2,311.9	3,099.4
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss) (net of tax)	5,410.7	4,058.4	2,702.8	9,469.1	2,292.3	3,036.2
10	Total comprehensive income (net of tax) (8+9)	13,892.0	12,300.4	10,872.3	26,192.4	19,644.0	37,871.9
	Attributable to:						
	Owners of the Parent Company	13,895.2	12,305.9	10,876.6	26,201.1	19,658.3	37,895.1
	Non-controlling interest	(3.2)	(5.5)	(4.3)	(8.7)	(14.3)	(23.2)
	Out of total comprehensive income above,						
	Profit after tax attributable to:						
	Owners of the Parent Company	8,484.5	8,247.5	8,173.8	16,732.0	17,366.0	34,858.8
	Non-controlling interest	(3.2)	(5.5)	(4.3)	(8.7)	(14.3)	(23.1)
	Other comprehensive income/(loss) attributable to:						
	Owners of the Parent Company	5,410.7	4,058.4	2,702.8	9,469.1	2,292.3	3,036.3
	Non-controlling interest	-	-	-	-	-	(0.1)
11	Paid-up equity share capital (face value ₹ 1 per share)	580.8	580.8	580.8	580.8	580.8	580.8
12	Other equity						3,25,952.4
13	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	14.61	14.20	14.00	28.81	29.69	59.81
	(b) Diluted (in ₹)	14.61	14.20	14.00	28.81	29.69	59.81



u. - 4



Sl. No.	Particulars	As at	As at
		30.09.2025	31.03.2025
		Unaudited	Audited
	ASSETS		
1 Non-current assets			
Property, plant and equipment		1,29,874.2	1,18,950.2
Capital work-in-progress		30,394.5	32,660.0
Right-of-use assets		2,932.6	2,944.1
Goodwill		6,367.6	6,180.2
Other intangible assets		19,678.0	19,867.4
Intangible assets under development		18,553.7	16,339.6
Investments accounted for using the equity method		404.8	455.4
Financial assets			
Investments		2,261.6	2,061.6
Loans		71.2	67.4
Trade receivables		-	1,083.2
Other financial assets		5,524.9	5,377.1
Deferred tax assets (net)		14,409.2	12,929.6
Non-current tax assets (net)		3,798.1	4,370.8
Other non-current assets		4,698.5	2,938.5
Total non-current assets		2,38,968.9	2,26,225.1
2 Current assets			
Inventories		1,11,918.8	1,05,437.2
Financial assets			
Investments		10.2	0.1
Trade receivables		58,911.1	57,459.3
Cash and cash equivalents		54,016.4	55,689.5
Bank balances other than cash and cash equivalents		34,897.5	26,665.4
Loans		166.3	155.6
Other financial assets		2,251.7	2,619.5
Current tax assets (net)		18.2	27.8
Other current assets		24,296.9	23,570.2
Total current assets		2,86,487.1	2,71,624.6
TOTAL ASSETS (1+2)		5,25,456.0	4,97,849.7
	EQUITY AND LIABILITIES		
1 Equity			
Equity share capital		580.8	580.8
Other equity		3,49,830.4	3,25,952.4
Equity attributable to owners of the Parent Company		3,50,411.2	3,26,533.2
Non-controlling interest		(72.6)	(63.9)
Total equity		3,50,338.6	3,26,469.3
Liabilities			
2 Non-current liabilities			
Financial liabilities			
Borrowings		10,385.2	15,616.5
Lease liabilities		2,438.0	2,392.1
Others		17.6	141.0
Provisions		3,723.7	2,829.3
Deferred tax liabilities (net)		3,002.5	3,032.7
Other non-current liabilities		542.9	545.4
Total non-current liabilities		20,109.9	24,557.0
3 Current liabilities			
Financial liabilities			
Borrowings		64,403.6	63,800.3
Lease liabilities		718.2	819.8
Trade payables			
total outstanding dues of micro enterprises and small enterprises		1,279.2	862.3
total outstanding dues of creditors other than micro enterprises and small enterprises		46,226.8	41,026.2
Other financial liabilities		28,686.2	29,241.6
Other current liabilities		6,232.6	5,468.3
Provisions		3,398.8	2,755.6
Current tax liabilities (net)		4,062.1	2,849.3
Total current liabilities		1,55,007.5	1,46,823.4
TOTAL EQUITY AND LIABILITIES (1+2+3)		5,25,456.0	4,97,849.7



[Handwritten signature]



Sl. No.	Particulars	For the half year ended 30.09.2025	For the half year ended 30.09.2024
		Unaudited	Unaudited
1	CASH FLOW FROM OPERATING ACTIVITIES		
	Net profit before tax	24,827.2	25,313.5
	Adjustments for :		
	Depreciation, amortisation and impairment expense	8,348.9	7,864.6
	Allowance for expected credit losses (net)	72.4	188.1
	Liabilities no longer required written back	(15.5)	(22.2)
	Unrealised exchange loss/(gain) (net)	3,961.4	288.1
	Loss on sale of property, plant and equipment (net)	54.9	31.1
	Write-off of intangible assets under development (net)	17.8	4.1
	Share of loss of associates and joint ventures	(35.8)	10.9
	Profit on sale of investments	(0.3)	(53.8)
	Dividend income	(10.9)	-
	Finance costs	1,853.1	2,166.0
	Interest income	(1,731.0)	(1,521.3)
	Operating profit before working capital changes	37,342.2	34,269.1
	Movements in working capital:		
	(Increase)/decrease in inventories	(6,481.7)	(6,236.3)
	(Increase)/decrease in trade receivables	305.8	(6,041.8)
	(Increase)/decrease in other financial assets	341.3	(5,382.0)
	(Increase)/decrease in other assets	(672.6)	(3,505.5)
	Increase/(decrease) in trade payables	5,589.9	(606.3)
	Increase/(decrease) in provision for employee benefits	1,511.7	674.0
	Increase/(decrease) in other financial liabilities	(2,029.2)	3,066.0
	Increase/(decrease) in other liabilities	761.8	(2,180.8)
	Cash generated from operating activities	36,669.2	14,056.4
	Income taxes paid (net of refunds)	(7,818.6)	(7,532.2)
	Net cash generated from operating activities (A)	28,850.6	6,524.2
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment, including movement in capital work- in- progress, capital advances and capital creditors (net)	(13,631.6)	(7,970.8)
	Purchase of intangible assets and intangible assets under development	(2,135.5)	(830.0)
	Proceeds from sale of property, plant and equipment	87.1	427.8
	Purchase of controlling interest in subsidiaries	-	(121.5)
	Purchase of non-current investments	(120.5)	(65.0)
	Proceeds from sale of non-current investments	59.1	583.8
	(Purchase)/proceeds from sale of current investments (net)	(10.2)	(2.4)
	Movement in other bank balances	(8,255.3)	(510.0)
	Dividend received	10.9	-
	Interest received	1,761.9	1,405.9
	Net cash used in investing activities (B)	(22,234.1)	(7,082.2)
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Buy back of equity shares (including tax and transaction cost)	-	(9,302.4)
	Proceeds from non-current borrowings	3,483.4	2,782.6
	Repayment of non-current borrowings	(6,382.4)	(95.9)
	Proceeds/(repayment) of current borrowings (net)	(1,885.7)	14,695.5
	Interest paid	(1,795.9)	(2,069.2)
	Repayment of lease liabilities	(523.4)	(551.8)
	Dividend paid	(2,321.9)	(6.6)
	Net cash generated from financing activities (C)	(9,425.9)	5,452.2
	Net increase / (decrease) in cash and cash equivalents (A + B + C)	(2,809.4)	4,894.2
	Cash and cash equivalents at the beginning of the year	55,637.9	33,854.3
	Add: Cash and cash equivalents on acquisition of a subsidiary	-	6.6
	Effect of exchange differences on cash and cash equivalents	186.2	208.0
	Cash and cash equivalents at the end of the period	53,014.7	38,963.1
	Cash and cash equivalents comprise of:		
	Cash on hand	1.9	149.9
	Balance with banks		
	- in current account	22,927.2	19,522.7
	- in money market	1,254.6	1,027.6
	- in deposit account	29,832.7	18,339.5
	Cash and cash equivalents	54,016.4	39,039.7
	Overdraft used for cash and cash management	1,001.7	76.6
	Cash and cash equivalents considered for cash flows	53,014.7	38,963.1



Handwritten signature or initials.



NOTES:

- 1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on November 5, 2025. The results for the quarter and half year ended September 30, 2025 have been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2025.
- 4 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 5 During the quarter and half year ended September 30, 2025:
 - (i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025.
 - (ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025.
 - (iii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. through Helix Healthcare B.V., The Netherlands, (wholly owned subsidiary) on September 17, 2025.
 - (iv) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics (Malta) Limited through CuraTeQ Biologics B.V., The Netherlands, (wholly owned subsidiary) on September 26, 2025.
 - (v) Pharmacin B.V (wholly owned subsidiary of Agile Pharma BV) merged with Agile Pharma BV (wholly owned subsidiary of Helix Healthcare B.V., The Netherlands) w.e.f. July 1, 2025.
 - (vi) Helix Healthcare B.V, The Netherlands, (wholly owned subsidiary) has transferred its 100% stake in CuraTeQ Biologics s.r.o., Czech Republic (wholly owned subsidiary) to CuraTeQ Biologics B.V, The Netherlands (wholly owned subsidiary) w.e.f. July 29, 2025.
 - (vii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Chile SpA through Helix Healthcare B.V, (wholly owned subsidiary) on October 07, 2025.
 - (viii) The Company, incorporated a step-down subsidiary, Eugia Pharma Chile SpA through Eugia Pharma B.V, (wholly owned subsidiary) on October 07, 2025.
- 6 During the current quarter, Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in the quarter and half year ended September 30, 2025.

By Order of the Board
For Aurobindo Pharma Limited



K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195



Place: Hyderabad
Date :November 5, 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/loss after tax and total comprehensive income/loss of its associates and joint ventures for the quarter and half year ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of subsidiaries, associates and joint ventures listed in Annexure I.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 21 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total assets of ₹ 338,563.1 million as at September 30, 2025, total revenue of ₹ 48,760.1 million and ₹ 94,836.3 million for the quarter and half year ended September 30, 2025 respectively, total net profit after tax of ₹ 1,937.2 million and ₹ 3,846.2 million for the quarter and half year ended September 30, 2025 respectively, total comprehensive income (net) of ₹ 1,930.3 million and ₹ 3,839.3 million for the quarter and half year ended September 30, 2025 respectively and net cash inflows of ₹ 3,005.3 million for the half year ended September 30, 2025, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

u

7. The unaudited consolidated financial results includes the interim financial information of 51 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of ₹ 72,501.4 million as at September 30, 2025, total revenue of ₹ 16,280.8 million and ₹ 31,040.6 million for the quarter and half year ended September 30, 2025 respectively, total profit/(loss) after tax (net) of ₹ 100.8 million and ₹ (52.5) million for the quarter and half year ended September 30, 2025 respectively, total comprehensive profit/(loss) of ₹ 100.8 million and ₹ (52.5) million for the quarter and half year ended September 30, 2025 respectively and net cash inflows of ₹ 2,593.7 million for the half year ended September 30, 2025, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of profit after tax of ₹ 16.6 million and ₹ 35.8 million for the quarter and half year ended September 30, 2025 and total comprehensive income of ₹ 16.6 million and ₹ 35.8 million for the quarter and half year ended September 30, 2025, as considered in the Statement, in respect of 2 associates and 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 25213649BMOEPV6450)

Place: Hyderabad
Date: November 05, 2025

Annexure I to the Independent Auditor's Report on Review of Interim Consolidated Financial Results

The interim unaudited consolidated financial results include results of the following entities:

S.No	Name of Component	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auro Peptides Ltd	India	Direct Subsidiary
9	Apitoria Pharma Private Limited	India	Direct Subsidiary
10	Auroactive Pharma Private Limited	India	Direct Subsidiary
11	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
12	AuroZest Private Limited	India	Direct Subsidiary
13	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
14	Eugia Pharma Specialities Ltd	India	Direct Subsidiary
15	GLS Pharma Limited	India	Direct Subsidiary
16	TheraNyM Biologics Private Limited	India	Direct Subsidiary
17	Auro Pharma Limited (formerly known as Auro Trading Private Limited)	India	Direct Subsidiary
18	Aurobindo Pharma Foundation	India	Direct Subsidiary
19	Auro Vaccines Private Limited	India	Step-Down Subsidiary
20	Agile Pharma B.V.	The Netherlands	Step-Down Subsidiary
21	Milpharm Limited	United Kingdom	Step-Down Subsidiary
22	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidiary
23	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidiary
24	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidiary
25	Pharmacin B.V. (Merged with Agile Pharma B.V. w.e.f July 01, 2025)	The Netherlands	Step-Down Subsidiary
26	Aurovitas Pharma Polska	Poland	Step-Down Subsidiary
27	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidiary
28	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidiary
29	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidiary
30	Arrow Generiques SAS	France	Step-Down Subsidiary
31	1980 Puren Pharma GmbH, Germany	Germany	Step-Down Subsidiary
32	Puren Pharma GmbH & Co., KG	Germany	Step-Down Subsidiary
33	Aurovitas Spain SA	Spain	Step-Down Subsidiary
34	Aurobindo Pharma B.V.	The Netherlands	Step-Down Subsidiary
35	Aurovitas Spol s.r.o	Czech Republic	Step-Down Subsidiary
36	Apotex Europe B.V.	The Netherlands	Step-Down Subsidiary
37	Aurovitas Nederland B.V	The Netherlands	Step-Down Subsidiary
38	Sameko Farma B.V.	The Netherlands	Step-Down Subsidiary
39	Leidapharm B.V.	The Netherlands	Step-Down Subsidiary
40	Marel B.V.	The Netherlands	Step-Down Subsidiary
41	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidiary
42	Aurobindo NV/SA	Belgium	Step-Down Subsidiary
43	CuraTeQ Biologics s.r.o.	Czech Republic	Step-Down Subsidiary
44	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidiary
45	Eugia Pharma (Malta) Limited	Malta	Step-Down Subsidiary
46	Eugia (UK) Limited	United Kingdom	Step-Down Subsidiary
47	Auro Pharma Inc.	Canada	Step-Down Subsidiary
48	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary

S.No	Name of Component	Country	Relationship
49	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
50	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
51	Aurobindo Pharma Colombia S.A.S	Colombia	Step-Down Subsidiary
52	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
53	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
54	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
55	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
56	Aurosulud SA De CV	Mexico	Step-Down Subsidiary
57	Auro PR Inc.	Puerto Rico	Step-Down Subsidiary
58	Eugia Pharma Inc.	Canada	Step-Down Subsidiary
59	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
60	Eugia Pharma Industria Farmaceutica Limitada	Brazil	Step-Down Subsidiary
61	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
62	Eugia Pharma Colombia S.A.S.	Colombia	Step-Down Subsidiary
63	PT Aurogen Pharma	Indonesia	Step-Down Subsidiary
64	Aurolife Pharma LLC	USA	Step-Down Subsidiary
65	Auro Health LLC	USA	Step-Down Subsidiary
66	Auro AR LLC	USA	Step-Down Subsidiary
67	Auro Vaccines LLC	USA	Step-Down Subsidiary
68	AuroLogistics LLC	USA	Step-Down Subsidiary
69	Acrotech Biopharma Inc	USA	Step-Down Subsidiary
70	Auro Science LLC	USA	Step-Down Subsidiary
71	Auro Packaging LLC	USA	Step-Down Subsidiary
72	Vespyr Brands, LLC (Formerly known as Nurya Brands Inc)	USA	Step-Down Subsidiary
73	Eugia Inc.	USA	Step-Down Subsidiary
74	Eugia US LLC	USA	Step-Down Subsidiary
75	Eugia US Manufacturing LLC	USA	Step-Down Subsidiary
76	Eugia Steriles Private Limited	India	Step-Down Subsidiary
77	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
78	Qule Pharma Private Limited	India	Step-Down Subsidiary
79	Eugia SEZ Private Limited	India	Step-Down Subsidiary
80	Auro Pharma LLC	Russia	Step-Down Subsidiary
81	Purple Bellflower, South Africa (w.e.f. April 30, 2024)	South Africa	Step-Down Subsidiary
82	Ace Laboratories Limited (w.e.f. June 28, 2024)	United Kingdom	Step-Down Subsidiary
83	Cresedemo Pharma LLC (w.e.f. June 13, 2025)	USA	Step-Down Subsidiary
84	Curateq Biologics B.V (w.e.f May 28, 2025)	The Netherlands	Step-Down Subsidiary
85	Aurobindo Pharma (Malaysia) SDN. BHD. (w.e.f September 17, 2025)	Malaysia	Step-Down Subsidiary
86	CuraTeQ Biologics (Malta) Limited (w.e.f September 26, 2025)	Malta	Step-Down Subsidiary
87	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
88	Raidurgam Developers Limited	India	Joint venture
89	Tergene Biotech Limited	India	Joint venture
90	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
91	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate